人巨细胞病毒分离株中，由HLA A*0201等位基因呈递的pp65(495 - 503)表位序列自然突变的发生率较低。
Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates.
作者信息
Zaia J A, Gallez-Hawkins G, Li X, Yao Z Q, Lomeli N, Molinder K, La Rosa C, Diamond D J
机构信息
Department of Virology, Beckman Research Institute of the City of Hope, Duarte, California 91010, USA.
出版信息
J Virol. 2001 Mar;75(5):2472-4. doi: 10.1128/JVI.75.5.2472-2474.2001.
Abstract
To determine if mutations of an immunodominant HLA-restricted cytomegalovirus (CMV) peptide sequence occur in nature, the sequence corresponding to the HLA A*0201-specific peptide CMVpp65(495-503) was determined in 50 human CMV isolates. Rare mutations were detected; 6 of 50 were silent mutations at the amino terminus of the peptide, while 3 of 50 were mutations of the native methionine residue to isoleucine (M499I). The observed M499I mutation in three isolates decreased cytolytic targeting.
摘要
为了确定免疫显性的HLA限制性巨细胞病毒（CMV）肽序列的突变是否在自然情况下发生，我们在50株人CMV分离株中测定了与HLA A*0201特异性肽CMVpp65(495 - 503)相对应的序列。检测到罕见突变；50株中有6株在肽的氨基末端发生沉默突变，而50株中有3株将天然甲硫氨酸残基突变为异亮氨酸（M499I）。在三株分离株中观察到的M499I突变降低了细胞溶解靶向作用。
相似文献
1
Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates.人巨细胞病毒分离株中，由HLA A*0201等位基因呈递的pp65(495 - 503)表位序列自然突变的发生率较低。
J Virol. 2001 Mar;75(5):2472-4. doi: 10.1128/JVI.75.5.2472-2474.2001.
2
Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles.多种HLA等位基因呈递的巨细胞病毒pp65新型细胞毒性T淋巴细胞表位的鉴定。
Blood. 2004 Jan 15;103(2):630-8. doi: 10.1182/blood-2003-03-0824. Epub 2003 Aug 28.
3
Identification of the HLA-A24 peptide epitope within cytomegalovirus protein pp65 recognized by CMV-specific cytotoxic T lymphocytes.巨细胞病毒特异性细胞毒性T淋巴细胞识别的巨细胞病毒蛋白pp65内HLA - A24肽表位的鉴定。
Viral Immunol. 2001;14(4):369-77. doi: 10.1089/08828240152716619.
4
Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay.通过计算机算法和酶联免疫斑点测定法高效鉴定 HLA-A*2402 限制性巨细胞病毒特异性 CD8(+) T 细胞表位
Blood. 2001 Sep 15;98(6):1872-81. doi: 10.1182/blood.v98.6.1872.
5
Kinase-deficient CMVpp65 triggers a CMVpp65 specific T-cell immune response in HLA-A*0201.Kb transgenic mice after DNA immunization.
Scand J Immunol. 2002 Jun;55(6):592-8. doi: 10.1046/j.1365-3083.2002.01099.x.
6
Identification of HLA-A24-restricted CTL epitope encoded by the matrix protein pp65 of human cytomegalovirus.人巨细胞病毒基质蛋白pp65编码的HLA - A24限制性细胞毒性T淋巴细胞表位的鉴定
Immunol Lett. 2002 Aug 1;83(1):21-30. doi: 10.1016/s0165-2478(02)00073-1.
7
8
Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting.人巨细胞病毒pp65保守激酶结构域中的定点突变，同时保留细胞毒性T淋巴细胞靶向性。
Vaccine. 2001 Feb 8;19(13-14):1628-35. doi: 10.1016/s0264-410x(00)00423-0.
9
Induction of HLA-G-restricted human cytomegalovirus pp65 (UL83)-specific cytotoxic T lymphocytes in HLA-G transgenic mice.在HLA-G转基因小鼠中诱导HLA-G限制的人巨细胞病毒pp65（UL83）特异性细胞毒性T淋巴细胞。
J Gen Virol. 2003 Feb;84(Pt 2):307-317. doi: 10.1099/vir.0.18735-0.
10
Soluble recombinant CMVpp65 spanning multiple HLA alleles for reconstitution of antiviral CD4+ and CD8+ T-cell responses after allogeneic stem cell transplantation.可溶性重组 CMVpp65 跨越多个 HLA 等位基因，用于重建异基因干细胞移植后抗病毒的 CD4+和 CD8+ T 细胞反应。
J Immunother. 2010 Jan;33(1):60-72. doi: 10.1097/CJI.0b013e3181b56dcc.
引用本文的文献
1
Optimisation of the cultured ELISpot/Fluorospot technique for the selective investigation of SARS-CoV-2 reactive central memory T cells.用于选择性研究SARS-CoV-2反应性中央记忆T细胞的培养ELISpot/荧光斑点技术的优化
Front Immunol. 2025 Apr 15;16:1547220. doi: 10.3389/fimmu.2025.1547220. eCollection 2025.
2
Development of a Vaccine against Human Cytomegalovirus: Advances, Barriers, and Implications for the Clinical Practice.抗人巨细胞病毒疫苗的研发：进展、障碍及对临床实践的启示
Vaccines (Basel). 2021 May 25;9(6):551. doi: 10.3390/vaccines9060551.
3
Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.用重叠十五肽致敏的供体T细胞进行免疫治疗以治疗持续性巨细胞病毒感染或病毒血症。
Biol Blood Marrow Transplant. 2015 Sep;21(9):1663-78. doi: 10.1016/j.bbmt.2015.05.015. Epub 2015 May 29.
4
Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine.新型豚鼠特异性干扰素-γ酶联免疫斑点试验的开发以及用安卡拉痘苗病毒（MVA）载体GP83疫苗免疫后豚鼠巨细胞病毒GP83特异性细胞免疫反应的特征分析
Vaccine. 2014 Jun 30;32(31):3963-70. doi: 10.1016/j.vaccine.2014.05.011. Epub 2014 May 20.
5
T cell receptor αβ diversity inversely correlates with pathogen-specific antibody levels in human cytomegalovirus infection.人类巨细胞病毒感染中 T 细胞受体 αβ 多样性与病原体特异性抗体水平呈负相关。
Sci Transl Med. 2012 Apr 4;4(128):128ra42. doi: 10.1126/scitranslmed.3003647.
6
Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant.PADRE-巨细胞病毒（CMV）和破伤风-CMV 融合肽疫苗联合或不联合 PF03512676 佐剂的安全性和免疫原性临床评价。
J Infect Dis. 2012 Apr 15;205(8):1294-304. doi: 10.1093/infdis/jis107. Epub 2012 Mar 7.
7
Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies.热休克蛋白 70/肽复合物：产生抗病毒 T 细胞的有效介质，特别是针对低前体频率。
J Transl Med. 2011 Oct 12;9:175. doi: 10.1186/1479-5876-9-175.
8
Systemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challenge.用三价质粒DNA和灭活鼠巨细胞病毒（MCMV）疫苗进行全身启动-加强免疫，可在全身或黏膜MCMV攻击后提供针对病毒复制的长期保护。
J Virol. 2005 Jan;79(1):159-75. doi: 10.1128/JVI.79.1.159-175.2005.
本文引用的文献
1
Enhanced immune activity of cytotoxic T-lymphocyte epitope analogs derived from positional scanning synthetic combinatorial libraries.源自位置扫描合成组合文库的细胞毒性T淋巴细胞表位类似物的免疫活性增强。
Blood. 2001 Mar 15;97(6):1776-86. doi: 10.1182/blood.v97.6.1776.
2
Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.健康个体中针对人巨细胞病毒pp65、IE1-外显子4、gB、pp150和pp28的细胞毒性T淋巴细胞（CTL）反应：对IE1特异性CTL流行率的重新评估
J Infect Dis. 2000 May;181(5):1537-46. doi: 10.1086/315445. Epub 2000 May 15.
3
4
5
6
Evaluation of a quantitative plasma PCR plate assay for detecting cytomegalovirus infection in marrow transplant recipients.用于检测骨髓移植受者巨细胞病毒感染的定量血浆PCR平板检测法的评估
J Clin Microbiol. 1997 Mar;35(3):788-90. doi: 10.1128/jcm.35.3.788-790.1997.
7
The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL.人类细胞毒性T淋巴细胞（CTL）对巨细胞病毒的反应以结构蛋白pp65为主导：pp65特异性CTL的频率、特异性和T细胞受体使用情况。
J Virol. 1996 Nov;70(11):7569-79. doi: 10.1128/JVI.70.11.7569-7579.1996.
8
Recognition of human cytomegalovirus gene products by HCMV-specific cytotoxic T cells.人巨细胞病毒特异性细胞毒性T细胞对人巨细胞病毒基因产物的识别。
Virology. 1996 Aug 1;222(1):293-6. doi: 10.1006/viro.1996.0424.
9
Human cytomegalovirus pp65 lower matrix phosphoprotein harbours two transplantable nuclear localization signals.人巨细胞病毒pp65低基质磷蛋白含有两个可移植的核定位信号。
J Gen Virol. 1996 Jun;77 ( Pt 6):1151-7. doi: 10.1099/0022-1317-77-6-1151.
10
Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes.鉴定人巨细胞病毒主要晚期基质蛋白pp65作为CD8 +病毒特异性细胞毒性T淋巴细胞的靶抗原。
J Med Virol. 1994 May;43(1):103-10. doi: 10.1002/jmv.1890430119.
Zotero 插件